Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Eluxadoline in Pediatric IBS-D
NCT04880876Phase 3Enrolling by invitation
- Sponsor
- AbbVie Inc.
- Start
- Aug 2021
- Primary completion
- Dec 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of eluxadoline in Irritable bowel syndrome with diarrhea (IBS-D), sponsored by AbbVie Inc.. Started Aug 2021; status: enrolling by invitation.
02
Drugs
eluxadoline
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT04880876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04880876.